<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01863849</url>
  </required_header>
  <id_info>
    <org_study_id>FluvalAB-H-YL2013</org_study_id>
    <nct_id>NCT01863849</nct_id>
  </id_info>
  <brief_title>Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection</brief_title>
  <official_title>Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 μgHA/Strain/0.5mL) for the Use in the Season 2013/2014 in Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fluart Innovative Vaccine Ltd, Hungary</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fluart Innovative Vaccine Ltd, Hungary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess immunogenicity of a single intramuscular injection of Fluval AB suspension for&#xD;
      injection (trivalent, seasonal influenza vaccine, active ingredient content: 15 μgHA/0.5mL of&#xD;
      seasonal A/H1N1, A/H3N2 and B influenza antigens each), as measured by haemagglutination&#xD;
      inhibition (HI) test.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the study:&#xD;
&#xD;
      To assess immunogenicity and safety of Fluval AB seasonal influenza vaccine with 3 x 15 μgHA&#xD;
      active ingredient in two age groups (18-59 years and ≥60 years) in accordance with&#xD;
      CPMP/BWP/214/96: &quot;Note for Guidance on Harmonization of Requirements for Influenza Vaccines&quot;,&#xD;
      12 March 1997&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To assess immunogenicity of a single intramuscular injection of Fluval AB suspension for&#xD;
      injection (trivalent, seasonal influenza vaccine, active ingredient content: 15 μgHA/0.5mL of&#xD;
      seasonal A/H1N1, A/H3N2 and B influenza antigens each), as measured by haemagglutination&#xD;
      inhibition test.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      In this open label, uncontrolled, multi-centre immunogenicity and tolerability study subjects&#xD;
      were enrolled in two groups according to age (18-59 years and ≥60 years) and assigned to the&#xD;
      following vaccine group:&#xD;
&#xD;
      Group 1: Single injection of Fluval AB suspension for injection. Subjects were observed for&#xD;
      30 minutes after the injection on Visit 1 (Day 0) for any immediate reactions.&#xD;
&#xD;
      All subjects were requested to complete a diary card to record local reactions (injection&#xD;
      site pain, erythema, swelling, induration and ecchymosis) and systemic reactions (fever,&#xD;
      shivering, headache, malaise, fatigue, sweating, nausea, myalgia and arthralgia) started on&#xD;
      the day of vaccination on Visit 1 (Day 0) until 7 (seven) days following that.&#xD;
&#xD;
      All adverse events were collected during the period of Visit 1 (Day 0) to Visit 2 (between&#xD;
      Day 21 and Day 28).&#xD;
&#xD;
      Serum samples for immunogenicity assays were collected immediately before immunization on&#xD;
      Visit 1 (Day 0) and on Visit 2 (between Day 21 and Day 28) in all subjects. Immunogenicity&#xD;
      was evaluated by HI test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 22, 2013</start_date>
  <completion_date type="Actual">September 17, 2013</completion_date>
  <primary_completion_date type="Actual">September 17, 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>parallel-group, in two age groups</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Geometric Mean Titre Ratio, A/H1N1 Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement (Age group 1): ≥ 2.5 Requirement (Age group 2): ≥ 2.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Geometric Mean Titre Ratio, A/H3N2 Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement (Age group 1): ≥ 2.5 Requirement (Age group 2): ≥ 2.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Geometric Mean Titre Ratio, B Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement (Age group 1): ≥ 2.5 Requirement (Age group 2): ≥ 2.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion, A/H1N1 Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Percentage of subjects seroconverted or had a significant increase in titres&#xD;
Requirement (Age group 1): &gt; 40 % Requirement (Age group 2): &gt; 30 %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion, A/H3N2 Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Percentage of subjects seroconverted or had a significant increase in titres&#xD;
Requirement (Age group 1): &gt; 40 % Requirement (Age group 2): &gt; 30 %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion, B Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Percentage of subjects seroconverted or had a significant increase in titres&#xD;
Requirement (Age group 1): &gt; 40 % Requirement (Age group 2): &gt; 30 %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection, A/H1N1 Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Percentage of subjects seroprotected&#xD;
Requirement (Age group 1): &gt; 70 % Requirement (Age group 2): &gt; 60 %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection, A/H3N2 Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Percentage of subjects seroprotected&#xD;
Requirement (Age group 1): &gt; 70 % Requirement (Age group 2): &gt; 60 %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection, B Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Percentage of subjects seroprotected&#xD;
Requirement (Age group 1): &gt; 70 % Requirement (Age group 2): &gt; 60 %</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Influenza Prophylaxis</condition>
  <arm_group>
    <arm_group_label>Age group 1: adults (18-59 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age group 2: elderly (&gt; 60 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination with Fluval AB suspension for injection</intervention_name>
    <description>Single intramuscular injection with Fluval AB suspension for injection in both age groups</description>
    <arm_group_label>Age group 1: adults (18-59 years)</arm_group_label>
    <arm_group_label>Age group 2: elderly (&gt; 60 years)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult persons aged 18 to 59 years, elderly persons aged ≥60 years from both sexes,&#xD;
             mentally competent;&#xD;
&#xD;
          -  Are in good health (as determined by vital signs and existing medical condition) or&#xD;
             are in stable medical condition. Subjects will not be excluded with known adequately&#xD;
             treated clinically significant organ or systemic diseases (e.g. asthma or diabetes),&#xD;
             such that, in the opinion of the investigator, the significance of the disease will&#xD;
             not compromise the subject's participation in the study;&#xD;
&#xD;
          -  Female volunteers aged 18-59 years (i.e. participants of childbearing potential) with&#xD;
             a negative result from the urine pregnancy test prior to vaccination who agrees to use&#xD;
             an acceptable contraception method or abstinence throughout the trial and not become&#xD;
             pregnant for the duration of the study;&#xD;
&#xD;
          -  Capability of participants to understand and comply with planned study procedures;&#xD;
&#xD;
          -  Participants provide written Informed Consent (IC) prior to initiation of study&#xD;
             procedures;&#xD;
&#xD;
          -  Absence of existence of any exclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, breast feeding or positive urine pregnancy test at baseline prior to&#xD;
             vaccination. Female subjects who are able to bear children but not willing to use an&#xD;
             acceptable contraception method for the duration of the study.&#xD;
&#xD;
          -  Known hypersensitivity to eggs, chicken protein, thiomersal, formaldehyde, gentamycin,&#xD;
             ciprofloxacin, neomycin, vancomycin or any other component of the vaccine;&#xD;
&#xD;
          -  History of Guillain-Barré syndrome;&#xD;
&#xD;
          -  History of neurological symptoms or signs, or anaphylactic shock following&#xD;
             administration of any vaccine;&#xD;
&#xD;
          -  Serious disease, such as cancer, autoimmune disease, advanced arteriosclerotic&#xD;
             disease, complicated diabetes mellitus, acute or progressive hepatic disease, acute or&#xD;
             progressive renal disease, congestive heart failure;&#xD;
&#xD;
          -  Immunosuppressive therapy within 36 months prior to vaccination;&#xD;
&#xD;
          -  Concomitant corticosteroid therapy, including high-dose inhaled corticosteroids;&#xD;
&#xD;
          -  Receipt of immunostimulants;&#xD;
&#xD;
          -  Receipt of parenteral immunoglobulin, blood products and/or plasma derivate within 3&#xD;
             months prior to vaccination;&#xD;
&#xD;
          -  Suspected or known HIV, HBV or HCV infection;&#xD;
&#xD;
          -  Acute disease and/or axillary temperature ≥37oC within 3 days prior to vaccination;&#xD;
&#xD;
          -  Vaccine therapy within 4 weeks prior to vaccination;&#xD;
&#xD;
          -  Influenza vaccination (any kind) within 6 months prior to vaccination;&#xD;
&#xD;
          -  Experimental drug therapy within 4 weeks prior to vaccination;&#xD;
&#xD;
          -  Concomitant participation in another clinical study;&#xD;
&#xD;
          -  Any condition which, in the opinion of the investigator, may interfere with the&#xD;
             evaluation of the study;&#xD;
&#xD;
          -  Past or current psychiatric disease of the volunteer that upon judgement of the&#xD;
             investigator may have effect on the objective decision-making of the volunteer;&#xD;
&#xD;
          -  Alcohol or drug abuse of the participant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zsolt Németh</last_name>
    <role>Study Chair</role>
    <affiliation>Fluart Innovative Vaccines Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Family Doctor's Office</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>District Doctor's Office</name>
      <address>
        <city>Pilisvorosvar</city>
        <zip>H-2085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>District Doctor's Office</name>
      <address>
        <city>Szentendre</city>
        <zip>H-2000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 23, 2013</study_first_submitted>
  <study_first_submitted_qc>May 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <results_first_submitted>February 17, 2021</results_first_submitted>
  <results_first_submitted_qc>March 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2021</results_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uncontrolled</keyword>
  <keyword>open</keyword>
  <keyword>multi-centre</keyword>
  <keyword>immunogenicity and tolerability</keyword>
  <keyword>two groups according to age (18-59 years and ≥60 years)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Age Group 1: Adults (18-59 Years)</title>
          <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.&#xD;
Vaccination with Fluval AB suspension for injection: Single intramuscular injection with Fluval AB suspension for injection in both age groups</description>
        </group>
        <group group_id="P2">
          <title>Age Group 2: Elderly (&gt; 60 Years)</title>
          <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.&#xD;
Vaccination with Fluval AB suspension for injection: Single intramuscular injection with Fluval AB suspension for injection in both age groups</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Primary analysis is conducted on the PP population.</population>
      <group_list>
        <group group_id="B1">
          <title>Age Group 1: Adults (18-59 Years)</title>
          <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
        </group>
        <group group_id="B2">
          <title>Age Group 2: Elderly (&gt;60 Years)</title>
          <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.1" spread="9.69"/>
                    <measurement group_id="B2" value="69.8" spread="6.87"/>
                    <measurement group_id="B3" value="58.1" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Geometric Mean Titre Ratio, A/H1N1 Strain</title>
        <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement (Age group 1): ≥ 2.5 Requirement (Age group 2): ≥ 2.0</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Adults (18-59 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Elderly (&gt;60 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Geometric Mean Titre Ratio, A/H1N1 Strain</title>
          <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement (Age group 1): ≥ 2.5 Requirement (Age group 2): ≥ 2.0</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>Ratio of Day 0 and Day 21-28 titres</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" lower_limit="2.63" upper_limit="3.72"/>
                    <measurement group_id="O2" value="3.17" lower_limit="2.65" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Geometric Mean Titre Ratio, A/H3N2 Strain</title>
        <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement (Age group 1): ≥ 2.5 Requirement (Age group 2): ≥ 2.0</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Adults (18-59 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Elderly (&gt; 60 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Geometric Mean Titre Ratio, A/H3N2 Strain</title>
          <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement (Age group 1): ≥ 2.5 Requirement (Age group 2): ≥ 2.0</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>Ratio of Day 0 and Day 21-28 titres</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" lower_limit="2.92" upper_limit="4.38"/>
                    <measurement group_id="O2" value="3.86" lower_limit="3.19" upper_limit="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Geometric Mean Titre Ratio, B Strain</title>
        <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement (Age group 1): ≥ 2.5 Requirement (Age group 2): ≥ 2.0</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Adults (18-59 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Elderly (&gt; 60 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Geometric Mean Titre Ratio, B Strain</title>
          <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement (Age group 1): ≥ 2.5 Requirement (Age group 2): ≥ 2.0</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>Ratio of Day 0 and Day 21-28 titres</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" lower_limit="2.96" upper_limit="4.32"/>
                    <measurement group_id="O2" value="4.29" lower_limit="3.45" upper_limit="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion, A/H1N1 Strain</title>
        <description>Percentage of subjects seroconverted or had a significant increase in titres&#xD;
Requirement (Age group 1): &gt; 40 % Requirement (Age group 2): &gt; 30 %</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Adults (18-59 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Elderly (&gt; 60 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion, A/H1N1 Strain</title>
          <description>Percentage of subjects seroconverted or had a significant increase in titres&#xD;
Requirement (Age group 1): &gt; 40 % Requirement (Age group 2): &gt; 30 %</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>percentage of subjects seroconverted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion, A/H3N2 Strain</title>
        <description>Percentage of subjects seroconverted or had a significant increase in titres&#xD;
Requirement (Age group 1): &gt; 40 % Requirement (Age group 2): &gt; 30 %</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Adults (18-59 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Elderly (&gt; 60 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion, A/H3N2 Strain</title>
          <description>Percentage of subjects seroconverted or had a significant increase in titres&#xD;
Requirement (Age group 1): &gt; 40 % Requirement (Age group 2): &gt; 30 %</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28</population>
          <units>percentage of subjects seroconverted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5"/>
                    <measurement group_id="O2" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion, B Strain</title>
        <description>Percentage of subjects seroconverted or had a significant increase in titres&#xD;
Requirement (Age group 1): &gt; 40 % Requirement (Age group 2): &gt; 30 %</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Adults (18-59 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Elderly (&gt; 60 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion, B Strain</title>
          <description>Percentage of subjects seroconverted or had a significant increase in titres&#xD;
Requirement (Age group 1): &gt; 40 % Requirement (Age group 2): &gt; 30 %</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28</population>
          <units>percentage of subjects seroconverted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2"/>
                    <measurement group_id="O2" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection, A/H1N1 Strain</title>
        <description>Percentage of subjects seroprotected&#xD;
Requirement (Age group 1): &gt; 70 % Requirement (Age group 2): &gt; 60 %</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Adults (18-59 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Elderly (&gt; 60 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection, A/H1N1 Strain</title>
          <description>Percentage of subjects seroprotected&#xD;
Requirement (Age group 1): &gt; 70 % Requirement (Age group 2): &gt; 60 %</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>percentage of subjects seroprotected</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9"/>
                    <measurement group_id="O2" value="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection, A/H3N2 Strain</title>
        <description>Percentage of subjects seroprotected&#xD;
Requirement (Age group 1): &gt; 70 % Requirement (Age group 2): &gt; 60 %</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Adults (18-59 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Elderly (&gt; 60 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection, A/H3N2 Strain</title>
          <description>Percentage of subjects seroprotected&#xD;
Requirement (Age group 1): &gt; 70 % Requirement (Age group 2): &gt; 60 %</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>percentage of subjects seroprotected</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection, B Strain</title>
        <description>Percentage of subjects seroprotected&#xD;
Requirement (Age group 1): &gt; 70 % Requirement (Age group 2): &gt; 60 %</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Adults (18-59 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Elderly (&gt; 60 Years)</title>
            <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection, B Strain</title>
          <description>Percentage of subjects seroprotected&#xD;
Requirement (Age group 1): &gt; 70 % Requirement (Age group 2): &gt; 60 %</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>percentage of subjects seroprotected</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7"/>
                    <measurement group_id="O2" value="78.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21-28 days after vaccination</time_frame>
      <desc>Subjects were observed for 30 minutes after the injection on Visit 1 (Day 0) for any immediate reactions.&#xD;
All subjects were requested to complete a diary card to record local and systemic reactions started on the day of vaccination on Visit 1 (Day 0) until 7 (seven) days following that.&#xD;
All adverse events were collected during the period of Visit 1 (Day 0) to Visit 2 (between Day 21 and Day 28).</desc>
      <group_list>
        <group group_id="E1">
          <title>Age Group 1: Adults (18-59 Years)</title>
          <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
        </group>
        <group group_id="E2">
          <title>Age Group 2: Elderly (&gt; 60 Years)</title>
          <description>Intervention: Vaccination with Fluval AB suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <description>fever</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>vaccination site pain</sub_title>
                <description>pain at vaccination site</description>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="59"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>vaccination site swelling</sub_title>
                <description>swelling at vaccination site</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="59"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>vaccination site erythema</sub_title>
                <description>erythema at vaccination site</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>vaccination site induration</sub_title>
                <description>induration at vaccination site</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>hyperhidrosis</sub_title>
                <description>sweat</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>vaccination site haematoma</sub_title>
                <description>haematoma at vaccination site</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgia</sub_title>
                <description>muscle pain</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>arthralgia</sub_title>
                <description>joint pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The disclosure restriction on the PI is that the sponsor in the frames of the general confidentiality agreement is that the PI cannot release any information concerning the study without the prior consent of the sponsor. To further specification is provided.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Zsolt Németh</name_or_title>
      <organization>Fluart Innovative Vaccines Ltd</organization>
      <phone>+3620 ext 4197020</phone>
      <email>info@fluart.hu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

